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If you are an editor, author, reviewer, or
reader of medical journals, or if you depend
on your doctor or health care provider
getting unbiased information from medical
journals, then the 1,500 documents now
hosted on the PLoS Medicine Web site [1]
should make you very concerned and angry.
Because, quite simply, the story told in these
documents amounts to one of the most
compelling expositions ever seen of the
systematic manipulation and abuse of schol-
arly publishing by the pharmaceutical
industry and its commercial partners in their
attempt to influence the health care deci-
sions of physicians and the general public.
Here’s just one sample thread [2] that
gives an idea of the topsy-turvy world
invented by the pharmaceutical and medical
writing companies involved. While readers
expect and assume that the named academic
authors on a paper carried out the piece of
work and then wrote up their article or
review informed by their professional qual-
ifications and expertise, instead we see a
prime example of ‘‘ghostwriting’’: a writing
company was commissioned to produce a
manuscript on a piece of research to fit the
d r u gc o m p a n y ’ sn e e d sa n dthen ap e r s o nw a s
identified to be the ‘‘author’’:
An email from a writer employed by
the medical writing company, De-
signWrite, to employees of Wyeth,
the company that performed the
study, and Parthenon (another med-
ical writing company) on November
10, 2003 concerning manuscripts on
Totelle (a brand of hormone re-
placement therapy manufactured by
Wyeth) tells the story concisely.
‘‘Thanks to all who have reviewed
and approved the manuscripts… I
have received no word on authors for the
Totelle 2 mg bone manuscript P3(2), and
need input on this matter before this
manuscript can move forwards.’’ [our
emphasis added]
PLoS Medicine became involved in this
particular ghostwriting story when we
intervened in an ongoing court case [1]
in which women were suing Wyeth, the
manufacturers of Prempro, a hormone
replacement therapy. During the discov-
ery process for this case, one of the lawyers
representing injured women in the litiga-
tion, Jim Szaller of Cleveland, Ohio,
became aware of many documents that
laid out in detail the company’s (mostly
successful) attempts to publish papers
written by unacknowledged professional
medical writers in which the message,
tone, and content had been determined by
the company but the paper was subse-
quently nominally ‘‘authored’’ by respect-
ed academics—in sum a coordinated and
carefully monitored campaign of ghost-
writing. Our interest was not in the
specific drugs, but in the issue of ghost-
writing itself, a topic we have long been
interested in and published on [3–6] The
intervention, presented by lawyers from
public interest law firm Public Justice
(http://www.publicjustice.net), and a sim-
ilar one from the New York Times, was
successful. On July 24, 2009, US District
Judge William R. Wilson, Jr., in Little
Rock, Arkansas, granted the Motions of
the Interveners, and the similar Motion of
the lawyers representing the women, to
make the discovery materials public as of
July 31.
This is not the place to review every-
thing written on this topic. Others have
written about ghostwriting campaigns
concerning single drugs that have led to
catastrophic health effects [7], and how
even research papers and clinical trials are
affected by ghost authors [7,8]. What’s
clear is that ghostwriting can no longer be
considered one of the ‘‘dirty little secrets’’
of medical publishing that nothing can be
done about. While editors, medical
schools, and universities have turned a
blind eye to, or at the least failed to tackle
head-on the pervasive presence of ghost-
writing, drug companies and medical
education and communication companies
have built a vast and profitable ghostwrit-
ing industry. Recruitment of academic
‘‘authors’’ appears, within some academic
circles, to have come to be considered
acceptable, and marketing campaigns are
no longer orchestrated around paid dis-
play advertisements but instead center on
‘‘evidence’’ provided by seemingly respect-
able academic review articles, original
research articles, and even reports of
clinical trials. What, a cynical reader
might ask, can I truly trust as being
unbiased? The answer is that, sadly, for
some or even many journal articles, we
just don’t know.
So what can be done? The documents
that have been made available are a
substantial step forward in advancing
knowledge of this practice and explaining
the mechanics of how ghostwriting cam-
paigns are organized, and will add to the
evidence base. By making them easily and
openly accessible we hope that others will
quickly delve into the documents and
analyze them in detail (we have yet not
done so in the interest of speed in making
them publicly available). But we also hope
that the papers not only will become the
subject of academic scrutiny but will help
to guide the way to identifying reforms
that will eventually stamp ghostwriting
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companies are beholden to their share-
holders, and the drive for profit takes
center stage, it is naı ¨ve to think that
companies will put their own houses in
order.
Over the past several years some
journals and editors’ organizations [9,10],
and even some individual medical writers
[11], have pursued what might be called a
war of attrition against the practice by
requiring contributorship statements for
authors and publishing them, insisting on
the naming of all who were involved in
writing, requiring detailed competing in-
terest statements, and detailing and pub-
lishing the provenance of non-research
articles. Editors’ bodies such as the
International Committee of Medical Jour-
nal Editors (ICMJE) expressly define
criteria for authorship in biomedical
publications [12], and the World Associ-
ation of Medical Editors (WAME) devel-
oped a specific policy on ghostwriting [10]
initiated by commercial companies that
calls the practice dishonest, unacceptable,
and sanctionable. But it seems that these
tactics are simply not enough to prevent
ghostwriting, and are being sidestepped by
those involved. Although medical writers
can and do have a legitimate place in
assisting in the preparation of manuscripts
(and, of course, academics and pharma-
ceutical companies can have legitimate
and appropriate relations, and not all
papers in this archive will have been
written by ghost authors), attempting to
hide the presence of ghostwriters or the
involvement of writers beyond technical
support (such as copyediting) is unaccept-
able. We’d argue, therefore, that all
involved must adopt a much tougher
approach of complete nontolerance to
practices that aim to conceal authors or
where the involvement of medical writers
goes beyond technical support.
What might this mean in practice for
journals? Primarily, it would mean a sea
change in the thinking and behavior of
editors, who should create—and be pre-
pared to enforce—journal policies clarify-
ing that involvement with ghostwriting is a
serious and punishable breach of publica-
tion ethics. Of course, prevention is key:
possible measures could include requiring
statements upon submission from academ-
ic authors about involvements by any
company whose products are mentioned
(positively or negatively, directly or indi-
rectly) in the commissioning of a third
party to provide editorial assistance, man-
uscript preparation, or submission of the
paper.
But journal polices should also include
enforceable sanctions. For example, if
nothing is declared on submission but
inappropriate involvement of a medical
writer subsequently comes to light, any
papers where this breach is substantiated
should be immediately retracted and those
authors found to have not declared such
interest should be banned from any
subsequent publication in the journal and
their misconduct reported to their institu-
tions.
In the case of the documents deposited
here, a good start, and a signal of the
seriousness of journals’ intent, would be
the formal retraction of all the papers
mentioned in which ghostwriting has been
conclusively shown. Institutions whose
academics are shown to be involved
should investigate as a matter of urgency.
It’s time to get serious about tackling
ghostwriting. As has been shown in the
documents released after the Vioxx scan-
dal [7], this practice can result in lasting
injury and even deaths as a result of
prescribers and patients being misin-
formed about risks. Without action, the
practice will undoubtedly continue. How
did we get to the point that falsifying the
medical literature is acceptable? How did
an industry whose products have contrib-
uted to astounding advances in global
health over the past several decades come
to accept such practices as the norm?
Whatever the reasons, as the pipeline for
new drugs dries up and companies in-
creasingly scramble for an ever-diminish-
ing proportion of the market in ‘‘me-too’’
drugs, the medical publishing and phar-
maceutical industries and the medical
academic community have become locked
into a cycle of mutual dependency, in
which truth and a lack of bias have come
to be seen as optional extras. Medical
journal editors need to decide whether
they want to roll over and just join the
marketing departments of pharmaceutical
companies. Authors who put their names
to such papers need to consider whether
doing so is more important than having a
medical literature that can be believed in.
Politicians need to consider the harm done
by an environment that incites companies
into insane races for profit rather than for
medical need. And companies need to
consider whether the arms race they have
started will in the end benefit anyone.
After all, even drug company employees
get sick; do they trust ghost authors?
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